Novel treatment

US4784999A · kind A · utility

Assignee

• Beecham-Wuelfing GmbH & Co. KG · DE

Inventors

• Dieter Angersbach · Gronau, DE
• Charles D. Nicholson · Glasgow, GB
• Joachim Goring · Gronau, DE
• Brian Morgan · Lymington, GB
• Jonathan Arch · Harlow, GB

Key dates

• Filing date: Sep 11, 1987
• Grant date: Nov 15, 1988
• Expiry date: Sep 11, 2007

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method for the treatment of cerebral vascular and neuronal degenerative disorders associated with learning, memory and cognitive dysfunctions including cerebral senility, multi-infarct dementia and senile dementia of the Alzheimer type and/or peripheral vascular disease and/or proliferative skin disease in mammals, such as humans, which comprises administering to the mammal in need of such treatment an effective amount of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine or a pharmaceutically acceptable salt thereof.